Grifols improves patient care by providing accurate diagnoses and ensuring the highest safety standards throughout the treatment journey. Grifols Diagnostic researches and develops innovative solutions for blood and plasma donor screening and the clinical diagnosis of diseases.
Our product pipeline and portfolio are built on cutting-edge solutions that improve detection of certain infectious diseases and enable comprehensive blood typing to support the safety of our plasma-based treatments. We’re also adding to our strengths in clinical diagnostics, including genetic testing as well as immunoassays aimed at diagnosing disease and monitoring treatments, part of our commitment to precision medicine for better patient outcomes.
An example is our Alpha ID™ cheek swab, which has already screened more than 1 million patients for alpha-1 antitrypsin deficiency syndrome,2 a form of chronic obstructive pulmonary disease (COPD). More recently, at the outset of the COVID-19 pandemic, we developed a highly sensitive molecular test in record time to facilitate early detection of the SARS-CoV-2 virus. Our nucleic acid testing (NAT) platform is used more than any other technology in the world to analyze blood donations and keep blood supplies safer.3